No profile data available.
Crispr Therapeutics AG (CRSP) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Zug, Switzerland.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$581.60 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $10.00 million. Its market capitalization was $5.54 billion as of October 5, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 5, 2026.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Crispr Therapeutics reported $0 in revenue for fiscal year 2025, down 100.0% from $35.00 million in fiscal year 2024. In Q2 2026 revenue was $10.00 million.
$5.54 billion as of October 5, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Ionis Pharmaceuticals, Inc. (IONS), Amneal Pharmaceuticals, Inc. (AMRX), Ligand Pharmaceuticals Incorporated (LGND), Grifols, S.a. (GRFS).